| Abstrakt: |
Objectives: Colorectal adenocarcinoma is the fourth leading cause of cancer-related mortality worldwide. These tumors are heterogeneous in terms of genomic alterations, immune response of the microenvironment, drug responsiveness, and biological behavior. Physiologically and pathologically, programmed cell death ligand 1 (PD-L1) is a key immune-regulatory molecule that suppresses immune response. PD-L1 expression on tumor cell has been implicated as a cause of immune evasion by tumor cells in many cancers. However, its activity in colorectal carcinomas is still under study. The aim of this study is to correlate PD-L1 marker expression with patient demographics, clinicopathological features, and TNM (t umor size, n ode involvement, and m etastasis status) stage, and to find if there exists any significant correlation between them. Materials and Methods: The present study is a 3-year retrospective analytical study conducted in a tertiary care hospital in South India. Specimens were routinely fixed, processed, and cut. Hematoxylin and eosin–stained sections and corresponding PD-L1-stained sections were analyzed and data were tabulated. Statistical analysis: Results were tabulated and statistical analysis was done using Statistical Package for the Social Sciences (SPSS) software (version 24). The chi-squared test was used to calculate the value of significance (p value). Results: PD-L1 expression on tumor cells was significantly associated with female gender, right-sided tumors, poorly differentiated tumors, higher number of tumor-infiltrating lymphocytes, and higher T and N statuses. Conclusion: High PD-L1 expression on tumor cells is a marker for poor prognosis. A subset of colorectal adenocarcinoma may benefit with anti-PD-L1-targeted therapy. [ABSTRACT FROM AUTHOR] |
